{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-090423","form_type":"8-K","ticker":"LIMN","cik":"0001971387","company_name":"Liminatus Pharma, Inc.","filed_at":"2026-08-04T20:30:44+00:00","discovered_at":"2026-08-04T20:33:00.254207+00:00","generated_at":"2026-08-04T20:33:31.135122+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Liminatus Pharma shareholders approve reverse stock split authorization up to 1-for-50 at annual meeting","bullets":["Elected Class I directors Nicholas Fernandez and Dr. Ji Yeon Baek with ~23.4M votes for each; broker non-votes 8.8M.","Ratified WithumSmith+Brown as independent auditor for FY2026; 31.5M for, 0.89M against, 63k abstain.","Approved reverse stock split authorization up to 1-for-50 at Board's discretion to meet Nasdaq minimum bid price; 30.1M for, 2.3M against.","Quorum of 48.31% (32.4M shares) represented at the August 3, 2026 annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-090423","json":"https://secwatch.observer/filing/0001104659-26-090423.json","markdown":"https://secwatch.observer/filing/0001104659-26-090423.md","text":"https://secwatch.observer/filing/0001104659-26-090423.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926090423/0001104659-26-090423-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926090423/tm2622207d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T20:33:31.135122+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}